Wells Fargo’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
VCM
VPM
Wells Fargo's DNLI Position: Q1 2026 in Review
Wells Fargo reduced its Denali Therapeutics (DNLI) stake by 44% in Q1 2026, selling an estimated $1.71M and leaving 107,657 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3237.
Wells Fargo first reported a position in DNLI in Q4 2017 and has held it in 34 quarters since. The position peaked at $11.6M in Q2 2021. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Wells Fargo held 107,657 shares of Denali Therapeutics worth $2.07M as of Q1 2026.
- Wells Fargo sold 86,024 Denali Therapeutics shares in Q1 2026, an estimated $1.71M.
- Denali Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3237 holding.
- Wells Fargo first reported a position in Denali Therapeutics in Q4 2017 and has held it in 34 quarters since.
- Wells Fargo's Denali Therapeutics position peaked at $11.6M in Q2 2021.
- 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.